Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Ann Oncol 2018; 29: 1541–1547 (doi: 10.1093/annonc/mdy155) The following has been added to the ‘Disclosure’ section: “CLA reports fees for advisory work with Novartis Pharmaceuticals (specifically participation on a Steering Committee for a clinical trial).” Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerAnnals of OncologyVol. 29Issue 7PreviewThe phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer. Here, we report updated efficacy and safety data, together with exploratory biomarker analyses, from the MONALEESA-2 study. Full-Text PDF Open Access